About GENOSERA, INC.
Genosera is a clinical-stage gene therapy company founded in 2019, focused on developing transformative treatments for serious genetic diseases using a proprietary platform designed to enhance safety, durability, and ease of manufacturing.
Developing next generation gene therapies using an AAV-based delivery platform with a patent-pending dual-gene designTargeting rare diseases with high unmet need, including GNE Myopathy (GNEM), Lysosomal Acid Lipase Deficiency (LAL-D), and Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)Restoring gene function to stop disease progression, reverse damage, and improve quality of life
Is this your company?
Claim GENOSERA, INC. to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim GENOSERA, INC. & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.